Exhibit 99.2

Qualigen Therapeutics, Inc.

Unaudited Pro Forma Balance Sheet

As of March 31, 2025

(Giving Effect to the July 2025 Private Placement of Series A-3 Preferred Stock)

	For The Period Ended March 31, 2025
				Preferred Stock		Pro Forma
	As Reported			A-3		As Adjusted
ASSETS
Current assets
Cash and cash equivalents	$	30,210		$	4,257,938	$	4,288,148
Prepaid expenses and other current assets		565,765			—		565,765
Short-term notes receivable, net of allowance for credit losses of $557,000 at March 31, 2025 and $360,000 at December 31, 2024		2,229,563			—		2,229,563
Other current assets		20,000			—		20,000
Total current assets		2,845,538			4,257,938		7,103,476
Other assets		2,000			—		2,000
Total Assets	$	2,847,538		$	4,257,938	$	7,105,476
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable	$	1,530,735		$	-	$	1,530,735
Accrued expenses and other current liabilities		210,104			—		210,104
Warrant liabilities		229,950			—		229,950
Promissory notes, net of premium of $157,385 at March 31, 2025 and $- at December 31, 2024		843,615			—		843,615
Total current liabilities		2,814,404			—		2,814,404
Commitments and Contingencies (Note 10)
Stockholders’ Equity (Deficit)
Preferred stock, $0.001 par value; 15,000,000 shares authorized; 3,021 and 6,256 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	$	2,823,094		$	4,257,938	$	7,081,032
Preferred stock, $0.001 par value; 15,000,000 shares authorized; 3,021 and 6,256 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		—			—		—
Common stock, $0.001 par value; 225,000,000 shares authorized; 1,625,310 and 736,431 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		66,203			—		66,203
Additional paid-in capital		122,851,582			—		122,851,582
Accumulated deficit		(125,707,745	)		—		(125,707,745	)
Total Stockholders’ Equity		33,134			4,257,938		4,291,071
Total Liabilities & Stockholders’ Equity	$	2,847,538		$	4,257,938	$	7,105,475